Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
17.21
-0.76 (-4.23%)
At close: Mar 20, 2026, 4:00 PM EDT
17.52
+0.31 (1.78%)
After-hours: Mar 20, 2026, 7:54 PM EDT
Apellis Pharmaceuticals Revenue
In the year 2025, Apellis Pharmaceuticals had annual revenue of $1.00B with 28.46% growth. Apellis Pharmaceuticals had revenue of $199.91M in the quarter ending December 31, 2025, a decrease of -5.94%.
Revenue (ttm)
$1.00B
Revenue Growth
+28.46%
P/S Ratio
2.19
Revenue / Employee
$1,358,298
Employees
739
Market Cap
2.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.00B | 222.42M | 28.46% |
| Dec 31, 2024 | 781.37M | 384.78M | 97.02% |
| Dec 31, 2023 | 396.59M | 321.17M | 425.83% |
| Dec 31, 2022 | 75.42M | 8.86M | 13.31% |
| Dec 31, 2021 | 66.56M | -184.08M | -73.44% |
| Dec 31, 2020 | 250.65M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Galapagos NV | 1.31B |
| Travere Therapeutics | 490.73M |
| Adaptive Biotechnologies | 276.98M |
| Syndax Pharmaceuticals | 172.35M |
| Day One Biopharmaceuticals | 158.18M |
| Nektar Therapeutics | 55.23M |
| Wave Life Sciences | 42.73M |
| Immunome | 6.94M |
APLS News
- 20 days ago - Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors - GlobeNewsWire
- 26 days ago - Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 27 days ago - Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 4 weeks ago - Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting - GlobeNewsWire
- 5 weeks ago - Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 - PRNewsWire
- 2 months ago - Apellis Valuation Ignores Empaveli Potential, Says Analyst - Benzinga
- 2 months ago - Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire